Rosacea
Recent clinical, regulatory, research and industry developments relating to this disease.
ORBS: Ocular Rosacea Biome Study
Therapeutic strategies focusing on immune dysregulation and neuroinflammation in rosacea.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 3 clinical trials expected to report results, the earliest in Q3 2027.
- Q3 2027Analysis of the Microbiome in Rosacea
- Q3 2027The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea: A Prospective Parallel Controlled Single-blind Cohort Study
- Q4 2028Pilot Studies Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
Clinical MilestonesViewHide
- 2026-06-08Analysis of the Microbiome in RosaceaResults expected Q3 2027
- 2026-03-24The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea: A Prospective Parallel Controlled Single-blind Cohort StudyResults expected Q3 2027
- 2026-02-18Pilot Studies Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With RosaceaResults expected Q4 2028
- 2026-01-01Treatment of Moderate-to-severe Papulopustular Rosacea With DeucravacitinibWithdrawn
- 2026-06-08ClinicalAnalysis of the Microbiome in RosaceaResults expected Q3 2027
- 2026-03-24ClinicalThe Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea: A Prospective Parallel Controlled Single-blind Cohort StudyResults expected Q3 2027
- 2026-02-18ClinicalPilot Studies Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With RosaceaResults expected Q4 2028
- 2026-01-01ClinicalTreatment of Moderate-to-severe Papulopustular Rosacea With DeucravacitinibWithdrawn
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Mirvaso is indicated for the symptomatic treatment of facial erythema of rosacea in adult… (2014)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes7
- Rosacea3
- Acne Vulgaris1
- Botulinum Toxins, Type A1
- Cosmetic Techniques1
- Dermatitis1
- Neuroinflammatory Diseases1
- Osteopontin1
Leading journals3
- Frontiers in immunology2
- American journal of clinical dermatology1
- Journal of cosmetic dermatology1
Leading researchers8
- Arents BWM1
- Calvisi L1
- Chang ALS1
- Chen X1
- Diaspro A1
- Fedorowicz Z1
- Hu H1
- Jung CJ1
Affiliations (unnormalised)6
- Amsterdam University Center1
- Graduate Institute of Medical Sciences1
- Greater Bay Biomedical Innocenter1
- Leiden University Medical Center1
- Maxillofacial Surgeon at the Rigeneralab Centre for Regenerative Medicine1
- Pegaso University1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
A cutaneous disorder primarily of convexities of the central part of the FACE, such as FOREHEAD; CHEEK; NOSE; and CHIN. It is characterized by FLUSHING; ERYTHEMA; EDEMA; RHINOPHYMA; papules; and ocular symptoms. It may occur at any age but typically after age 30. There are various subtypes of rosacea: erythematotelangiectatic, papulopustular, phymatous, and ocular (National Rosacea Society's Expert Committee on the Classification and Staging of Rosacea, J Am Acad Dermatol 2002; 46:584-7).
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.